01515 CR MEDICAL
- 4.170
- +0.040+0.97%
CR MEDICAL News
China Resources Medical's 2023 Profit Slides
China Resources Medical Holdings (HKG:1515) reported a profit attributable to owners of 257.7 million yuan for 2023, compared with 265.9 million yuan in the previous year, according to a Thursday fili
華潤醫療：2023 年度報告
Express News | Wantai Biotech successfully signed a regional strategic cooperation agreement with China Resources Medical Technology (Hebei) Co., Ltd.
CICC: Maintaining China Resources Healthcare's (01515) “Outperform the Industry” Rating Target Price of HK$5.6
The Zhitong Finance App learned that CICC released a research report stating that it maintained China Resources Healthcare's (01515) “outperforming the industry” rating and maintained 2024/2025 net profit of RMB551/715 billion, an increase of 113.8%/29.8% over the previous year, with a target price of HK$5.6. The company announced its 2023 results: revenue of RMB 10.108 billion, up 27.9% year on year; net profit to mother of RMB 258 million, a decrease of 3.1% year on year, in line with the forecast. CICC's main views are as follows: further expansion of the hospital network layout, hospital industry
China Resources Healthcare (01515.HK): Performance is in line with expectations, gross margin increased year-on-year
The 2023 results are in line with our expectations. The company announced the 2023 results: revenue of RMB 10.108 billion, up 27.9% year on year; net profit to mother of RMB 258 million, a decrease of 3.1% year on year, which is in line with me
China Resources Healthcare (01515.HK): Steady growth in hospital revenue and increasing profit contribution
Core view: The company disclosed its 23-year results announcement. The hospital business revenue grew steadily, and the adjusted division performance margin increased. Revenue for year 23 was 10.108 billion yuan, +79.8% year-on-year (if Liao Jian is not included in the same period in '22
CR MEDICAL To Go Ex-Dividend On June 7th, 2024 With 0.0661 HKD Dividend Per Share
March 20th - $CR MEDICAL(01515.HK)$ is trading ex-dividend on June 7th, 2024. Shareholders of record on June 11th, 2024 will receive 0.0661 HKD dividend per share on July 19th, 2024. The ex-divide
Hong Kong stock changes丨China Resources Medical rose more than 3%, revenue increased 27.9% year-on-year in 2023, and proposed a final interest rate of $0.06 per share
Gelonghui, March 20 | China Resources Healthcare (1515.HK) is now up 3.61% to HK$4.02, temporarily trading HK$14.86 million, with a current market value of HK$5.2 billion. China Resources Medical announced its annual results for the year ended December 31, 2023 yesterday evening. During the period, it achieved revenue of 10.108 billion yuan (RMB, same below), an increase of 27.9% over the previous year. Owners of the parent company should account for an annual profit of $258 million, and holders of common equity interests in the parent company should account for $0.20 per share (basic and diluted). It is recommended to distribute a final dividend of $0.06 per share. During the reporting period, the hospital business turnover was 94
Announcement Highlights: Xiaomi Q4's adjusted net profit increased 236.1% year on year; Xiaopeng Motor Q4's adjusted net loss decreased by 19.9% year on year
Li Ning's revenue in 2023 was 27.598 billion yuan, an increase of 7.0%; China Unicom's profit due to equity holders in 2023 was 18.7 billion yuan, an increase of 11.8% over the previous year.
China Resources Healthcare (01515) will pay a final dividend of $0.06 per share on July 19
According to Zhitong Finance App, China Resources Healthcare (01515) announced that it will pay a final dividend of RMB 0.06 per share for the year ended December 31, 2023 on July 19, 2024.
China Resources Healthcare (01515) announced annual results, with shareholders' share profit of 258 million yuan
China Resources Healthcare (01515) announced its annual results for the year ended December 31, 2023. The group reaped benefits, people...
CR MEDICAL: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | China Resources Healthcare (01515) fell by more than 5% and expected annual profit to drop to about 250 million yuan
China Resources Healthcare (01515) fell more than 5% in early trading. As of press release, it was down 4.75% to HK$4.01, with a turnover of HK$29.59,900.
Changes in Hong Kong stocks | China Resources Healthcare (01515) opened nearly 8% lower after the earnings alert and expected annual profit to fall to about 250 million yuan
The Zhitong Finance App learned that China Resources Healthcare (01515) opened nearly 8% lower after the announcement. As of press release, it fell 7.78% to HK$4.15, with a turnover of HK$830,000. According to the news, China Resources Medical issued an announcement. Based on currently available data and a preliminary assessment of the group, it is estimated that the net profit for the year ending December last year is about 250 million yuan, down from the stated profit of about 270 million yuan for the same period in 2022. According to the announcement, the changes in the Group's performance during the reporting period were mainly affected by two events, namely: acquisitions during the reporting period; and the Group's calculation of Huai'an Huaiyin Medical
China Resources Medical (01515) Fa Ying Guang expects profit attributable to parent company owners to drop to about 250 million yuan in 2023
China Resources Medical (01515) announced that the group expects the parent company's owner's profit to be about RMB 2 in 2023...
China Resources Medical (01515.HK) held a board meeting on March 19 to approve annual results
Gelonghui, Feb. 28, 丨 China Resources Medical (01515.HK) announced that a board meeting will be held on March 19, 2024 (Tuesday) to consider and approve the comprehensive annual results and announcements of the Company and its subsidiaries for the year ended 31 December 2023, consider the payment of a final dividend proposal (if any), and deal with other matters.
CR MEDICAL: PROFIT UPDATE
CR MEDICAL: DATE OF BOARD MEETING
Ministry of Finance: The total profit of state-owned enterprises in 2023 was 4633.28 billion yuan, up 7.4% year-on-year
From January to December, the main efficiency indicators of state-owned and state-owned enterprises across the country continued to grow steadily, and the upward trend was further consolidated.
Selected Announcements | Tencent made large repurchases for 3 consecutive days, totaling over HK$3 billion; Yuexiu Real Estate spent about 4.4 billion yuan to acquire land in Tianhe, Guangzhou
Clover Biotech announced positive data from a phase I clinical trial of SCB-219M, a targeted drug for tumor chemotherapy-related thrombocytopenia (CIT); Fu Hong Hanlin: Hansform® was approved for marketing in Indonesia to treat widespread small cell lung cancer.
Analysis
Price Target
No Data
